Value
8.8/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 8.5 |
| P/S | 8.7 |
| EV/EBITDA | 7.8 |
| Fwd P/E | 9.9 |
| PEG | 10.0 |
| Analyst target | 7.5 |
- ▸Forward P/E: 5.5x
- ▸PEG: 0.06
- ▸Attractively valued
HRMY · Why this verdict
Why Harmony Biosciences Holdings, I (HRMY) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score7.3/10
ConfidenceHIGH
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
A business with a wide economic moat, a Piotroski score of 9 out of 9, and 16% margins trades at a forward multiple of 6.1x with a PEG of 0.05 — implying the market is deeply discounting a franchise with durable return characteristics; the setup is held back by three earnings misses in the last four quarters and a sole-product revenue base that amplifies any execution stumble.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business earns strong returns with 16% margins, carries a Piotroski score of 9 out of 9, and is assessed as having a wide economic moat — yet the market prices it at a forward P/E of 6.1x and a PEG of 0.05, a valuation that appears to leave considerable earnings power unrecognized. Quality breakdown | If the quality advantage is real and durable, the forward earnings multiple should expand toward a mid-teens range over 12 months as the market re-rates the franchise on normalized earnings. | →Stable |
| CounterThree of the last four quarters missed consensus estimates; if the underlying earnings trajectory is genuinely deteriorating rather than temporarily disrupted, a single-digit forward multiple may be precisely correct rather than undervalued. | ||
All commercial revenue flows through a single product, and the manufacturing base depends on sole-source suppliers and manufacturers, leaving no buffer if that one revenue stream faces a demand, pricing, or supply interruption. Bear case | If this risk is not realized, product revenue should grow without any supply interruption and management should maintain or improve manufacturing redundancy disclosures over the next year. | ↓Deteriorating |
| CounterSole-product franchises often achieve dominant market share and strong pricing control within their niche; if market penetration continues to expand, concentration reflects competitive strength rather than structural fragility. | ||
The two most recent quarters each missed consensus — by 16% and 46% respectively — and three of the last four quarters have come in below estimates, producing an average earnings surprise of negative 10% and raising questions about whether guidance discipline has slipped. Earnings | If this concern is misplaced, earnings should beat or meet consensus in at least two of the next three reported quarters, with positive guidance revisions following. | ↓Deteriorating |
| CounterThe one beat in this period was a 25% upside surprise, and the earnings growth score stands at the top of its range; the misses may reflect lumpy, hard-to-forecast revenue rather than a structural downshift in profitability. | ||
At the current price, the reward-to-risk geometry produces a ratio near 1-to-1 — below the 1.5-to-1 threshold required to justify a new position — meaning an investor captures roughly $1 of upside for every $1 of downside accepted. Engine gate (failed) | For this pillar to resolve favorably, the reward-to-risk ratio should rise above 1.5 to 1 — either through a price pullback or through an upward revision to analyst targets — before the setup becomes actionable. | →Stable |
| CounterAnalyst consensus targets imply 30% upside from current levels; if execution stabilizes and momentum follows, the current geometry may represent a temporary dislocation rather than a permanent feature of the setup. | ||
The business earns strong returns with 16% margins, carries a Piotroski score of 9 out of 9, and is assessed as having a wide economic moat — yet the market prices it at a forward P/E of 6.1x and a PEG of 0.05, a valuation that appears to leave considerable earnings power unrecognized.
→StableQuality breakdown
- Expectation
- If the quality advantage is real and durable, the forward earnings multiple should expand toward a mid-teens range over 12 months as the market re-rates the franchise on normalized earnings.
CounterThree of the last four quarters missed consensus estimates; if the underlying earnings trajectory is genuinely deteriorating rather than temporarily disrupted, a single-digit forward multiple may be precisely correct rather than undervalued.
All commercial revenue flows through a single product, and the manufacturing base depends on sole-source suppliers and manufacturers, leaving no buffer if that one revenue stream faces a demand, pricing, or supply interruption.
↓DeterioratingBear case
- Expectation
- If this risk is not realized, product revenue should grow without any supply interruption and management should maintain or improve manufacturing redundancy disclosures over the next year.
CounterSole-product franchises often achieve dominant market share and strong pricing control within their niche; if market penetration continues to expand, concentration reflects competitive strength rather than structural fragility.
The two most recent quarters each missed consensus — by 16% and 46% respectively — and three of the last four quarters have come in below estimates, producing an average earnings surprise of negative 10% and raising questions about whether guidance discipline has slipped.
↓DeterioratingEarnings
- Expectation
- If this concern is misplaced, earnings should beat or meet consensus in at least two of the next three reported quarters, with positive guidance revisions following.
CounterThe one beat in this period was a 25% upside surprise, and the earnings growth score stands at the top of its range; the misses may reflect lumpy, hard-to-forecast revenue rather than a structural downshift in profitability.
At the current price, the reward-to-risk geometry produces a ratio near 1-to-1 — below the 1.5-to-1 threshold required to justify a new position — meaning an investor captures roughly $1 of upside for every $1 of downside accepted.
→StableEngine gate (failed)
- Expectation
- For this pillar to resolve favorably, the reward-to-risk ratio should rise above 1.5 to 1 — either through a price pullback or through an upward revision to analyst targets — before the setup becomes actionable.
CounterAnalyst consensus targets imply 30% upside from current levels; if execution stabilizes and momentum follows, the current geometry may represent a temporary dislocation rather than a permanent feature of the setup.
Per-dimension breakdown
Quality
8.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 6.8 |
| ROA | 7.7 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 9.4 |
| Current ratio | 9.5 |
| FCF quality | 7.0 |
| Moat | 9.0 |
| Rule of 40 | 8.2 |
| Piotroski F | 10.0 |
- ▸Strong margins: 19%
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
- ▸Rule of 40: 49 (pass)
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 30% YoY
Momentum
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 8.2 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 4.0 |
| Volume | 10.0 |
| vol acceleration | 2.0 |
- ▸Uptrend pullback (RSI 33) - buy opportunity
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
- ▸Volume surge (3.0x avg) on selloff
Sentiment
7.7/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.5 |
| Analyst rating | 7.1 |
| Price target | 8.8 |
- ▸LLM news sentiment: +0.50 (n=1)
- ▸Analyst upside: 34%
Insider
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 7.8 |
| notable moves | 7.0 |
- ▸Notable insider selling — $3,108,586 (0.139% of mkt cap)
- ▸Institutions accumulating
Peer rank
6.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.1 |
| quality rank | 7.7 |
| growth rank | 6.2 |
- ▸Superior ROE vs peers
Technical
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 10.0 |
| support resistance | 7.4 |
| 52w position | 6.6 |
Risk (lower is worse)
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.7 |
| days to cover | 5.4 |
| volatility | 0.5 |
| put call | 1.3 |
| implied vol | 0.0 |
| beta | 7.0 |
| debt equity | 9.4 |
- ▸Elevated put/call: 1.81
- ▸High IV: 84%
- ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 1.7 |
| news activity | 6.0 |
- ▸Earnings concerns: 2B/2M
- ▸Earnings in 12 days
How the verdict was assembled
Engine trigger
Value play: 50% MoS with quality 8.8. | News modifier -1 (STRONG_BUY_NOW → STRONG_BUY_WAIT).
Engine technical detail
verdict_path:
L4:PATH_A_VALUE_MOS33|L3:NEWS_MOD=-1|ENTRY_STICKY:WITHIN_BANDPassed (5)
- ASYMMETRY:1.7>=1.5
- INSIDER:OK
- NEWS_BOOST:ANALYST:0.50
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:4.2<4.5
Warning (2)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
- EARNINGS_PROXIMITY:12d<=14d (soft)
Reward-to-Risk
1.72
Upside
+16.5%
Downside
9.6%
Sizing output
STARTER
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The STRONG_BUY_WAIT verdict reflects the MOMENTUM gate's 4.2<4.5 outcome against Growth at 10.0 and asymmetric R:R of 1.72.
The strongest dimensions are Growth at 10.0, Value at 8.8, and Quality at 8.8; the weakest are Risk (lower is worse) at 3.9, Catalyst at 4.2, and Momentum at 4.2. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 1.72 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Wide Moat Bargain Valuation
Trip ifGross margin falls below 12% from the current 16% for 2 consecutive quarters.
- P2Earnings Miss Pattern Risk
Trip ifEPS beats consensus by more than 5% in 2 of the next 3 reported quarters.
- P3Single Product Sole Source Concentration
Trip ifA second commercial product contributes more than 20% of total quarterly revenue for 2 consecutive quarters.
- P4Asymmetry Too Thin At Spot
Trip ifReward-to-risk ratio rises above 1.5 as the share price falls to $31 or analyst price targets are revised above $45.